-
NIANCE Expands Beyond Products into a Global Beauty & Longevity Ecosystem
ZURICH, June 3, 2026 /PRNewswire/ — Swiss luxury beauty brand NIANCE is entering a new phase of growth with the launch of an integrated beauty and longevity ecosystem combining skincare, supplementation, diagnostics, treatments, recovery, and wellness experiences. Known for its science-backed approach to healthy aging, NIANCE has spent the past decade developing products to support beauty…
-
India's Sporting Future Will Be Built at League Level: Nicole Junkermann
India does not need to be told it is a major sports market. It already is. The bigger question now is how the next phase of growth is going to be built. According to Nicole Junkermann, founder of Gameday by NJF Holdings, the most significant long-term opportunities may lie beyond individual teams and headline…
-
Maverick Investments and Henox Announce Phased Development of 100 MW Green Data Centre and Cable Landing Station in Tamil Nadu
Initial Rs. 200 crore equity approved by Siraj Holdings with a structured platform being prepared to mobilise up to Rs. 50,000 crore over the project lifecycle Singapore | Chennai, India Maverick Investments Limited, part of the UAE-based Siraj Holdings Group, and Henox IT and Data Centers today outlined the first phase of Project Horizon, a…
-
Platinum Industries Announces Entry into Life Sciences; Collaborates with Dr. Abhigyan Upadhyay to Lead the New Enterprise, Rivadu Lifesciences Pvt. Ltd.
Strengthens leadership to build a research-driven and globally scalable model in high-value life sciences segments Mumbai, Maharashtra, India Platinum Industries Ltd. [NSE: PLATIND; BSE: 544134], an innovation-driven specialty chemicals company announced its strategic entry into the life sciences sector, marking a significant step in its next phase of growth. As part of this expansion, the…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
